Research Article
Tenascin-C Is Increased in Inflammatory Bowel Disease and Is Associated with response to Infliximab Therapy
Table 3
Relationship between Montreal classification and serum TNC levels.
| | Number | Serum TNC (ng/L) | value |
| CD | | | | Age at diagnosis | | | 0.579 | A1 (≤16) | 4 | 44.9 (44.3, 60.5) | | A2 (17–20) | 54 | 57.0 (43.9, 79.1) | | A3(>40) | 33 | 61.2 (45.6, 89.0) | | Location | | | 0.916 | L1 | 22 | 55.1 (48.8, 79.4) | | L2 | 30 | 65.6 (42.5, 89.0) | | L3 | 39 | 57.0 (44.7, 78.4) | | L4 | 0 | − | | Disease behavior | | | 0.278 | B1 | 51 | 57.0 (45.0, 81.2) | | B2 | 16 | 56.4 (38.6, 70.9) | | B3 | 24 | 68.5 (46.1, 87.8) | |
| UC | | | | Disease extension | | | 0.729 | E1 | 3 | 59.3 (54.2, 83.8) | | E2 | 13 | 71.1 (33.3, 102.4) | | E3 | 24 | 77.8 (48.8, 100.1) | |
|
|
CD, Crohn’s disease; UC, ulcerative colitis.
|